PCM4EU - Personalised Cancer Medicine for all EU citizens

PCM4EU is funded by the European Union (grant no. 101079984). #eu4health #eucancerplan

🚀 Advancing Personalized Cancer Medicine Across Europe: PCM4EU - Personalised Cancer Medicine for all EU citizens Final Conference in Leiden November 27-29, 2024, the PCM4EU (Personalised Cancer Medicine for All EU Citizens) consortium convened in Leiden, The Netherlands, for its final project conference. The three-day conference spotlighted advancements in diagnostics and treatments achieved during the initiative and fostered dialogue on the future of precision cancer medicine. Highlights included: 🔹 Discussions on tumor type definitions, biomarker identification, and molecular diagnostic strategies when merging clinical data from all the DRUP-like clinical trials. 🔹 Country-specific insights from several countries including Hungary, Lithuania, Italy, and others, showcasing national implementation successes. 🔹 Planning for a future project-independent governance body to sustain collaborative efforts between the DRUP-like clinical trials. Beyond the program, participants strengthened the collaboration through a formal dinner, museum tour, and networking opportunities. As PCM4EU wraps up, the collaboration will continue in new projects building on the results from PCM4EU including PRIME-ROSE and the coming Joint Action on PCM. Thank you for organizing a wonderful meeting Emanuela Lonardi, Hans Gelderblom and the rest of the DRUP-team. Kjetil Tasken, Hans Gelderblom, Emanuela Lonardi, Elisa Bjørgo, Tanja Juslin, Anders Edsjö, Hege Russnes, Åslaug Helland, Ulrik Niels Lassen, Bettina Ryll, Kristoffer Rohrberg, Ebba Hallersjö Hult, Loic Verlingue, Prof. Iwona Lugowska, MD, PhD https://lnkd.in/du3UTHv3

The Institute for Cancer Research and the Norwegian Cancer Symposium 2024 kicked-off the scientific program with an excellent Keynote talk by #DouglasHanahan from the Ludwig Institute for Cancer Research and Swiss Federal Institute of Technology Lausanne EPFL about the Hallmarks of Cancer 2024. Check out the full program: https://lnkd.in/de2VjHik Kjetil Tasken Oslo universitetssykehus Det medisinske fakultet UiO Oslo Cancer Cluster

Heading to #ESMO24? Curious about the extent of off-label drug use in oncology? Don’t miss the Mini Oral Session on Policy and Preventive Strategies, where work packes 4 in PRIME-ROSE will address this important issue in cancer care. Join Hans Timmer for his presentation: 1542MO - Mapping the Scale of Off-Label Use in Oncology: An Important Step in Harmonising Access 🗓️ Date: Monday, September 16th ⏰ Time: 14:45 - 16:15 Want to read more? Check out https://lnkd.in/d9YYwJcu for more details on how PRIME-ROSE will address the challenges with off-label use. Kjetil Tasken, Åslaug Helland, Hans Gelderblom, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Katriina Jalkanen, Atse Huisman, Elisa Bjørgo, Soemeya Haj Mohammad, Henk van der Pol. Ragnhild Falk, Arnoldo FRIGESSI, Eivind Hovig, Bettina Ryll, Ulrik Niels Lassen, Matthew Krebs, Sarah Halford, Gro Live Fagereng Julio Oliveira, Beatrice Mainoli, Loic Verlingue, Jean-Yves Blay, Edvard Abel, Ebba Hallersjö Hult, Edita Baltruskeviciene, Kristiina Ojamaa, Anni Lepland

Attending #ESMO24? Interested in how the DRUP-like clinical trials are sharing clinical data across borders? Don't miss our poster presentation, where we desribe how we share clinical outcome data from the different DRUP-like clinical trials. 📅 Poster Session 🗓️ Sunday, September 15th ⏰ 12:00 - 13:00 Join us to learn more about how collaborative efforts are enhancing the future of clinical trials. See you there! Special thank you to first author Tina Kringelbach! Elisa Bjørgo, PCM4EU - Personalised Cancer Medicine for all EU citizens, Åslaug Helland, Kjetil Tasken, Hans Gelderblom, Edvard Abel, Katriina Jalkanen, Tanja Juslin, Edita Baltruskeviciene, Anni Lepland, Bettina Ryll, Richard Rosenquist Brandell, Kristoffer Rohrberg, Ulrik Niels Lassen, Loic Verlingue, Julio Oliveira, Beatrice Mainoli, Soemeya Haj Mohammad, Hans Timmer, Henk van der Pol, Sarah Halford, Jean-Yves Blay, Giuseppe Curigliano Matthew Krebs, Kristiina Ojamaa, Claire L. Hyder, Aida Sarmiento Castro, MSc, PhD, Ebba Hallersjö Hult, Gro Live Fagereng

Check out this PCM4EU podcast episode about the importance of patient advocacy. Patient advocate Warnyta Minnaard discusses securing reimbursement for molecular profiling for Cancer of Unknown Primary (CUP) patients in the Netherlands. Previously underserved with limited treatment options, CUP patients now benefit from enhanced access to treatment and clinical trials through molecular profiling. Minnaard emphasizes the crucial role of patient advocacy in this progress. The host is Loic Verlingue: https://lnkd.in/djQdC_yW Hege Russnes Anders Edsjö Åslaug Helland Ulrik Niels Lassen Kjetil Tasken Ebba Hallersjö Hult Bettina Ryll Prof. Iwona Lugowska, MD, PhD Jean-Yves Blay PRIME-ROSE #eu4health #eucancerplan

The next Acta Oncologica Nordic Precision Cancer Medicine Symposium (NPCM) will take place in Oslo on September 15-17 2025. More information about this event and the program will be shared in the fall, but please save the dates already now! The first Acta Oncologica NPCM took place in September 2023 and included 20 renowned speakers from around the world. We promise an interesting and international program also in 2025! A special NPCM symposium collection based on the 2023 conference, has recently been published. Here you can read a.o. about the large EU-funded projects PCM4EU and PRIME-ROSE focusing on access to precision cancer medicine diagnostics and clinical trials as well as updates from several DRUP-like clinical trials, including IMPRESS-Norway: https://lnkd.in/dV-WRgX8 Åslaug Helland Sigbjørn Smeland Kjetil Tasken Hege Russnes Gro Live Fagereng Elisa Bjørgo Moya Berli Oslo University Hospital Acta Oncologica

Patient advocate Bettina Ryll and oncologist Loic Verlingue discuss the groundbreaking DRUP-like clinical trials (DLCTs) in this PCM4EU podcast: https://lnkd.in/diTW_DbN The DLCTs offer a last potential chance for patients with no other treatment options left, using targeted drugs to address specific molecular changes in tumour cells identified through advanced precision diagnostics. The innovative approach of DLCTs increases access to clinical trials and precision cancer medicine for cancer patients. Bettina Ryll Loic Verlingue Hans Gelderblom Åslaug Helland PRIME-ROSE Ebba Hallersjö Hult Hege Russnes Ulrik Niels Lassen Anders Edsjö Prof. Iwona Lugowska, MD, PhD Jean-Yves Blay

Warm congratulations to Kjetil Tasken on receiving the Excellent Reseacher Award at Oslo universitetssykehus today👏The committee highlighted his own research over several decades as well as his pioneering work in establishing precision cancer medicine in Norway and now also Europe, when justifying the 2024 award: https://lnkd.in/dMXSaW_Q Sigbjørn Smeland Åslaug Helland Hege Russnes Gro Live Fagereng Oslo universitetssykehus

See our paper in Acta Oncologica on what we are doing to advance #precisiononcology in the PCM4EU - Personalised Cancer Medicine for all EU citizens and #PRIMEROSE_EU projects funded by #eu4health #eucancerplan and #HorizonEurope #MissionCancer #PrecisionMedicine #DRUPtrials #ClinicalTrials #RareCancer #precisiononcology #datasharing: https://lnkd.in/dt68_yMA Hans Gelderblom Oslo Cancer Cluster Oslo University Hospital https://lnkd.in/dSD7bjpb